<?xml version="1.0" encoding="UTF-8"?>
<results title="activity">
 <result pre="AcademicSubjects/MED00860AcademicSubjects/MED00290 In vitro susceptibility testing for black grain eumycetoma causative" exact="agents" post="van de SandeWendy W J[], Erasmus Medical Center, University"/>
 <result pre="by large subcutaneous swellings. Inside the infected tissue, the causative" exact="agents" post="are found in grains. The most common causative agents"/>
 <result pre="causative agents are found in grains. The most common causative" exact="agents" post="form black grains and are sterile upon isolation. In"/>
 <result pre="assays developed have mainly been used to establish if causative" exact="agents" post="are inhibited in growth by various antifungal agents, but"/>
 <result pre="establish if causative agents are inhibited in growth by various" exact="antifungal" post="agents, but not for clinical decision making. For drug"/>
 <result pre="decision making, a range of MICs were found for each" exact="antifungal" post="agent. However, no clinical breakpoints have been established for"/>
 <result pre="the causative agents. For itraconazole, the MIC50 of most causative" exact="agents" post="was below the attainable serum levels, which might indicate"/>
 <result pre="caused by a large number of various agents.2,3 These causative" exact="agents" post="can be bacteria (actinomycetoma) or fungi (eumycetoma).2 Characteristic of"/>
 <result pre="more common than actinomycetoma2,3 and the most common eumycetoma causative" exact="agents" post="are Madurella mycetomatis (75.1%), Falciformispora senegalensis (6.2%), Trematosphaeria grisea"/>
 <result pre="forms white grains.4 Eumycetoma is treated with a combination of" exact="antifungal" post="agents and surgery. The treatment chosen is not dependent"/>
 <result pre="white grains.4 Eumycetoma is treated with a combination of antifungal" exact="agents" post="and surgery. The treatment chosen is not dependent on"/>
 <result pre="For fungal infections caused by Candida, Cryptococcus and Aspergillus species," exact="antifungal" post="susceptibility assays are routinely used to support clinicians in"/>
 <result pre="that infections due to susceptible Candida strains respond to appropriate" exact="antifungal" post="therapy in approximately 90% of cases, whereas infections due"/>
 <result pre="assays are used to guide patient management. For mycetoma, routine" exact="antifungal" post="susceptibility assays are not performed and no correlation between"/>
 <result pre="to date. However, efforts are under way to determine if" exact="antifungal" post="susceptibility assays can be of value in mycetoma management."/>
 <result pre="I will review the development and use of the current" exact="antifungal" post="susceptibility assays for eumycetoma causative agents. International guidelines for"/>
 <result pre="antifungal susceptibility assays for eumycetoma causative agents. International guidelines for" exact="antifungal" post="susceptibility testing For antifungal susceptibility testing, two international reference"/>
 <result pre="eumycetoma causative agents. International guidelines for antifungal susceptibility testing For" exact="antifungal" post="susceptibility testing, two international reference methods have been developed."/>
 <result pre="been used as a template in the development of an" exact="antifungal" post="susceptibility assay. Hyphae vs conidia As mentioned above, for"/>
 <result pre="starting inoculum (70â€&quot;80% transmission at 660Â nm) in the CLSI" exact="antifungal" post="susceptibility assay, similar MICs for amphotericin B and voriconazole"/>
 <result pre="used as a starting inoculum (2â€&quot;5Ã—104Â cfu/ml) in the EUCAST-based" exact="antifungal" post="susceptibility assay, again similar MICs for amphotericin B, posaconazole"/>
 <result pre="that have been used for endpoint reading in in vitro" exact="antifungal" post="susceptibility assays, including resazurin,17â€&quot;20 tetrazolium salts16,17,21â€&quot;24 and the luciferinâ€&quot;luciferase"/>
 <result pre="its derivative, alamarBlue, is also used in the commercial CLSI-based" exact="antifungal" post="susceptibility assay YeastOne.17,18 Resazurin is non-fluorescent and deep blue"/>
 <result pre="media and is often added at the beginning of an" exact="antifungal" post="susceptibility assay and incubated during the assay.24 To measure"/>
 <result pre="Over the years, several tetrazolium salts have been developed. For" exact="antifungal" post="susceptibility testing, 3-(4.5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT),16 2,3-bis(2-methoyloxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT)17,22,24,27 and"/>
 <result pre="release the formazan dye.16,24 To overcome this lysis step, tetrazolium" exact="derivatives" post="that produce water-soluble products such as XTT and WST-8"/>
 <result pre="used in the in vitro susceptibility assays for mycetoma causative" exact="agents" post="is XTT (FigureÂ 1B). To assess the effect of"/>
 <result pre="the culture media, the solvent and the fungus but no" exact="antifungal" post="agent) are used to normalize. The following formulas are"/>
 <result pre="- {\rm{Absorbanc}}{{\rm{e}}_{450nm}}\ {\rm{NC}}}}*100} \right) \end{eqnarray*}$$\end{document} Assays developed for mycetoma causative" exact="agents" post="Using the methodology described above, in vitro susceptibility assays"/>
 <result pre="include the common causative agent M. mycetomatis, the occasional causative" exact="agents" post="F. senegalensis, T. grisea, M. romeroi and Nigrograna mackinnonii"/>
 <result pre="grisea, M. romeroi and Nigrograna mackinnonii and the rare causative" exact="agents" post="Madurella pseudomycetomatis, Madurella fahalii, Madurella tropicana, Falciformispora tompkinsii, Emarellia"/>
 <result pre="species, endpoints can be read after 48Â h.19,39 Mycetoma causative" exact="agents" post="belonging to the order Sordariales usually grow well at"/>
 <result pre="performed at that temperature.36 For some of the mycetoma causative" exact="agents" post="belonging to the order Pleosporales, in vitro susceptibility needs"/>
 <result pre="Settings for in vitro susceptibility assays of black-grain eumycetoma causative" exact="agents" post="Species Prevalencea Starting inoculum Incubation temperature (Â°C) Incubation time"/>
 <result pre="and indicated as common (C), occasional (O) or rare (R)." exact="Antifungal" post="agents tested The antifungal susceptibility assays developed for mycetoma"/>
 <result pre="indicated as common (C), occasional (O) or rare (R). Antifungal" exact="agents" post="tested The antifungal susceptibility assays developed for mycetoma causative"/>
 <result pre="(C), occasional (O) or rare (R). Antifungal agents tested The" exact="antifungal" post="susceptibility assays developed for mycetoma causative agents have been"/>
 <result pre="agents tested The antifungal susceptibility assays developed for mycetoma causative" exact="agents" post="have been used to screen antifungal agents indicated for"/>
 <result pre="developed for mycetoma causative agents have been used to screen" exact="antifungal" post="agents indicated for the treatment of other fungal infections,"/>
 <result pre="for mycetoma causative agents have been used to screen antifungal" exact="agents" post="indicated for the treatment of other fungal infections, antifungal"/>
 <result pre="antifungal agents indicated for the treatment of other fungal infections," exact="antifungal" post="combinations, herbal medicine and drug screening purposes. Antifungal agents"/>
 <result pre="fungal infections, antifungal combinations, herbal medicine and drug screening purposes." exact="Antifungal" post="agents indicated for other fungal infections Using the CLSI-based"/>
 <result pre="infections, antifungal combinations, herbal medicine and drug screening purposes. Antifungal" exact="agents" post="indicated for other fungal infections Using the CLSI-based assays,"/>
 <result pre="indicated for other fungal infections Using the CLSI-based assays, several" exact="antifungal" post="agents have been assessed for their activity against mycetoma"/>
 <result pre="for other fungal infections Using the CLSI-based assays, several antifungal" exact="agents" post="have been assessed for their activity against mycetoma causative"/>
 <result pre="&amp;gt;256Â Âµg/ml).36 Table 3. In vitro susceptibilities of eumycetoma causative" exact="agents" post="MIC50 (Âµg/ml) (range; n) Species AMB KTZ ITZ PCZ"/>
 <result pre="(0.063â€&quot;4; 9) 4,39,42,48 Blood/serum level &amp;gt;1â€&quot;2a &amp;gt;0.5â€&quot;1.5a &amp;gt;1â€&quot;6a 2.8â€&quot;3b &amp;gt;20â€&quot;50a" exact="Antifungal" post="agents abbreviated as follows: amphotericin B (AMB), ketoconazole (KTZ),"/>
 <result pre="9) 4,39,42,48 Blood/serum level &amp;gt;1â€&quot;2a &amp;gt;0.5â€&quot;1.5a &amp;gt;1â€&quot;6a 2.8â€&quot;3b &amp;gt;20â€&quot;50a Antifungal" exact="agents" post="abbreviated as follows: amphotericin B (AMB), ketoconazole (KTZ), itraconazole"/>
 <result pre="al.50 Figure 2. M. mycetomatis cell demonstrating the compounds with" exact="antifungal" post="activity. The green antifungal agents are the agents that"/>
 <result pre="mycetomatis cell demonstrating the compounds with antifungal activity. The green" exact="antifungal" post="agents are the agents that have been able to"/>
 <result pre="cell demonstrating the compounds with antifungal activity. The green antifungal" exact="agents" post="are the agents that have been able to inhibit"/>
 <result pre="compounds with antifungal activity. The green antifungal agents are the" exact="agents" post="that have been able to inhibit growth at the"/>
 <result pre="growth are the echinocandins and 5-flucytosine. Of the mycetoma causative" exact="agents" post="belonging to the order Pleosporales, low MICs are also"/>
 <result pre="by 5-flucytosine, growth inhibition was noted for the Pleosporales causative" exact="agents" post="(TableÂ 3). Combining antifungal agents As demonstrated in the"/>
 <result pre="was noted for the Pleosporales causative agents (TableÂ 3). Combining" exact="antifungal" post="agents As demonstrated in the previous paragraph, M. mycetomatis"/>
 <result pre="noted for the Pleosporales causative agents (TableÂ 3). Combining antifungal" exact="agents" post="As demonstrated in the previous paragraph, M. mycetomatis is"/>
 <result pre="demonstrated in the previous paragraph, M. mycetomatis is inhibited by" exact="antifungal" post="agents belonging to the polyenes, azoles, allylamines and orotomides."/>
 <result pre="in the previous paragraph, M. mycetomatis is inhibited by antifungal" exact="agents" post="belonging to the polyenes, azoles, allylamines and orotomides. The"/>
 <result pre="enhanced growth inhibition occurs when itraconazole is combined with an" exact="antifungal" post="agent belonging to a different class of antifungal agents."/>
 <result pre="with an antifungal agent belonging to a different class of" exact="antifungal" post="agents. Therefore the combinations ketoconazoleâ€&quot;terbinafine, itraconazoleâ€&quot;terbinafine and itraconazoleâ€&quot;olorofim have"/>
 <result pre="in vivo G. mellonella grain model.51 Table 4. Combinations of" exact="antifungal" post="agents tested for M. mycetomatis Combination Number of strains"/>
 <result pre="vivo G. mellonella grain model.51 Table 4. Combinations of antifungal" exact="agents" post="tested for M. mycetomatis Combination Number of strains tested"/>
 <result pre="methanol extract 13 12.5Â Âµg/ml 30 Antiseptic solutions The XTT-based" exact="antifungal" post="susceptibility assay was also used to determine the in"/>
 <result pre="also used to determine the in vitro activity of the" exact="antiseptic" post="solutions 1% povidone iodine, 0.5% taurolidine Ringerâ€™s solution, 0.02%"/>
 <result pre="taurolidine Ringerâ€™s solution was used.29 Since the killing time for" exact="antiseptic" post="solutions is more important than the killing concentration, probably"/>
 <result pre="more important than the killing concentration, probably the most active" exact="antiseptic" post="solution against M. mycetomatis is 1% povidone iodine. Herbal"/>
 <result pre="been performed. All five studies investigated the therapeutic efficacy of" exact="antifungal" post="agents against M. mycetomatis. This has not been assessed"/>
 <result pre="performed. All five studies investigated the therapeutic efficacy of antifungal" exact="agents" post="against M. mycetomatis. This has not been assessed for"/>
 <result pre="in the in vitro susceptibility assays, hyphae are exposed to" exact="antifungal" post="agents, while in vivo hyphae are embedded in the"/>
 <result pre="This indicated that the grain was difficult to penetrate by" exact="antifungal" post="agents. Characteristic of the M. mycetomatis grain is the"/>
 <result pre="the grain. M. mycetomatis 1,8-dihydroxynaphthaleneâ€&quot;melanin did interfere with susceptibility to" exact="antifungal" post="agents.59 A four to five twofold dilution step increase"/>
 <result pre="target.59 Along with melanin, the extracellular matrix can protect against" exact="antifungal" post="agents. This matrix consists of proteins, chitin and polysaccharides,60â€&quot;63"/>
 <result pre="can serve as a protective barrier against chemical and biological" exact="antimicrobial" post="agents.64 Some of the compounds inside the fungal extracellular"/>
 <result pre="matrix, such as Î²-1,3-D-glucan and extracellular DNA, can physically bind" exact="antifungal" post="agents and thereby prevent the drugs from reaching the"/>
 <result pre="such as Î²-1,3-D-glucan and extracellular DNA, can physically bind antifungal" exact="agents" post="and thereby prevent the drugs from reaching the intended"/>
 <result pre="was completely resistant to itraconazole, voriconazole and posaconazole.65,66 The only" exact="antifungal" post="agent tested that did have some activity against the"/>
 <result pre="Besides looking at correlations between in vitro activity of standard" exact="antifungal" post="agents and in vivo efficacy, the in vitro susceptibility"/>
 <result pre="looking at correlations between in vitro activity of standard antifungal" exact="agents" post="and in vivo efficacy, the in vitro susceptibility assays"/>
 <result pre="from the pandemic and stasis boxes (blue) or commonly used" exact="antifungal" post="agents (red) and larval survival (%). The MIC50s for"/>
 <result pre="the pandemic and stasis boxes (blue) or commonly used antifungal" exact="agents" post="(red) and larval survival (%). The MIC50s for the"/>
 <result pre="box were determined in ÂµM, while the MIC50s of the" exact="antifungal" post="agents were determined in Âµg/ml. Correlation with therapeutic data"/>
 <result pre="were determined in ÂµM, while the MIC50s of the antifungal" exact="agents" post="were determined in Âµg/ml. Correlation with therapeutic data in"/>
 <result pre="fumigatus and A. terreus.67 The MIC50s obtained for most causative" exact="agents" post="of mycetoma are below the clinical breakpoints for the"/>
 <result pre="are above or below the serum levels obtained for each" exact="antifungal" post="agent. For most of the antifungal agents, attainable serum"/>
 <result pre="levels obtained for each antifungal agent. For most of the" exact="antifungal" post="agents, attainable serum levels have been determined (TableÂ 3).49"/>
 <result pre="susceptibility assays have been developed for the most common causative" exact="agents" post="of black-grain eumycetoma. These assays have been used to"/>
 <result pre="eumycetoma. These assays have been used to establish if causative" exact="agents" post="are inhibited in growth by various antifungal agents but"/>
 <result pre="establish if causative agents are inhibited in growth by various" exact="antifungal" post="agents but not for clinical decision making. For drug"/>
 <result pre="if causative agents are inhibited in growth by various antifungal" exact="agents" post="but not for clinical decision making. For drug discovery,"/>
 <result pre="and Laboratory Standards Institute. M38 reference method for broth dilution" exact="antifungal" post="susceptibility testing of filamentous fungi, 3rd ed. Wayne, PA:"/>
 <result pre="for the determination of broth dilution minimum inhibitory concentrations of" exact="antifungal" post="agents for conidia forming moulds. Basel, Switzerland: EUCAST; 2020."/>
 <result pre="the determination of broth dilution minimum inhibitory concentrations of antifungal" exact="agents" post="for conidia forming moulds. Basel, Switzerland: EUCAST; 2020. 10Al-HatmiAM,"/>
 <result pre="12PujolI, Fernandez-BallartJ, GuarroJ. Effect of inoculum form on in vitro" exact="antifungal" post="susceptibilities of Aspergillus spp. J Antimicrob Chemother. 2001;47(5):715â€&quot;8.11328793 13van"/>
 <result pre="2001;47(5):715â€&quot;8.11328793 13van de SandeWW, TavakolM, van VianenWet al.The effects of" exact="antifungal" post="agents to conidial and hyphal forms of Aspergillus fumigatus."/>
 <result pre="13van de SandeWW, TavakolM, van VianenWet al.The effects of antifungal" exact="agents" post="to conidial and hyphal forms of Aspergillus fumigatus. Med"/>
 <result pre="vitro susceptibility testing of dermatophytes and the activity of novel" exact="antifungal" post="agents. Antimicrob Agents Chemother. 2015;59(6):3675â€&quot;82.25870071 15SchmalreckA, WillingerB, CzaikaVet al.Susceptibility"/>
 <result pre="of the in vitro susceptibilities of Madurella mycetomatis to six" exact="antifungal" post="agents by using the Sensititre system in comparison with"/>
 <result pre="the in vitro susceptibilities of Madurella mycetomatis to six antifungal" exact="agents" post="by using the Sensititre system in comparison with a"/>
 <result pre="Antimicrob Agents Chemother. 2019;64(1):e01532â€&quot;19.31611353 19AhmedSA, de HoogGS, StevensDAet al.In vitro" exact="antifungal" post="susceptibility of coelomycete agents of black grain eumycetoma to"/>
 <result pre="19AhmedSA, de HoogGS, StevensDAet al.In vitro antifungal susceptibility of coelomycete" exact="agents" post="of black grain eumycetoma to eight antifungals. Med Mycol."/>
 <result pre="on reduction of a soluble tetrazolium salt, 2,3-bis[2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for" exact="antifungal" post="susceptibility testing of Aspergillus species. J Clin Microbiol. 2001;39(12):4256â€&quot;63.11724829"/>
 <result pre="microplate method for the proliferation assay of fungi and the" exact="antifungal" post="susceptibility testing using the colorimetric microbial viability assay. Lett"/>
 <result pre="Standards method of testing clinical yeast isolates for susceptibility to" exact="antifungal" post="agents. J Clin Microbiol. 1998;36(5):1450â€&quot;2.9574729 28AhmedSA, KloezenW, DuncansonFet al.Madurella"/>
 <result pre="2014;8(6):e2942.24945848 29EadieK, FahalA, van de SandeWWJ. In vitro activity of" exact="antiseptic" post="solutions against Madurella mycetomatis, implications on eumycetoma management. Br"/>
 <result pre="Br J Dermatol. 2015;172:1657â€&quot;9.25429729 30ElfadilH, FahalA, KloezenWet al.The in vitro" exact="antifungal" post="activity of Sudanese medicinal plants against Madurella mycetomatis, the"/>
 <result pre="PLoS Negl Trop Dis. 2015;9(3):e0003488.25768115 31KloezenW, MeisJF, Curfs-BreukerIet al.In vitro" exact="antifungal" post="activity of isavuconazole to Madurella mycetomatis. Antimicrob Agents Chemother."/>
 <result pre="HoogGS, van DiepeningenAD, Mahgoub elSet al.New species of Madurella, causative" exact="agents" post="of black-grain mycetoma. J Clin Microbiol. 2012;50(3):988â€&quot;94.22205798 37AhmedSA, KloezenW,"/>
 <result pre="paragrisea sp. nov. J Clin Microbiol. 2016;54(7):1738â€&quot;45.27076666 39FothergillAW, RinaldiMG, SuttonDA." exact="Antifungal" post="susceptibility testing of Exophiala spp.: a head-to-head comparison of"/>
 <result pre="al.Madurella mycetomatis is not susceptible to the echinocandin class of" exact="antifungal" post="agents. Antimicrob Agents Chemother. 2010;54(6):2738â€&quot;40.20350944 41collab: Drugs for Neglected"/>
 <result pre="April 24, 2020]. 42VenugopalPV, VenugopalTV, RamakrishnaESet al.Antimycotic susceptibility testing of" exact="agents" post="of black grain eumycetoma. J Med Vet Mycol. 1993;31(2):161â€&quot;4.8389847"/>
 <result pre="Venereol. 2020;34(8):1828â€&quot;34.32233084 44WalshTJ, PeterJ, McGoughDAet al.Activities of amphotericin B and" exact="antifungal" post="azoles alone and in combination against Pseudallescheria boydii. Antimicrob"/>
 <result pre="J Dermatol. 1993;34(1):27â€&quot;9.8240184 47GulmezD, DoganO, BoralBet al.In vitro activities of" exact="antifungal" post="drugs against environmental Exophiala isolates and review of the"/>
 <result pre="of Exophiala jeanselmei, with a case report and in vitro" exact="antifungal" post="susceptibility of the species. Med Mycol. 2010;48(2):318â€&quot;27.19642051 49AndesD, PascualA,"/>
 <result pre="susceptibility of the species. Med Mycol. 2010;48(2):318â€&quot;27.19642051 49AndesD, PascualA, MarchettiO." exact="Antifungal" post="therapeutic drug monitoring: established and emerging indications. Antimicrob Agents"/>
 <result pre="Chemother. 2009;53(1):24â€&quot;34.18955533 50DoltonMJ, PereraV, PontLGet al.Terbinafine in combination with other" exact="antifungal" post="agents for treatment of resistant or refractory mycoses: investigating"/>
 <result pre="2009;53(1):24â€&quot;34.18955533 50DoltonMJ, PereraV, PontLGet al.Terbinafine in combination with other antifungal" exact="agents" post="for treatment of resistant or refractory mycoses: investigating optimal"/>
 <result pre="Antimicrob Agents Chemother. 2014;58(1):48â€&quot;54.24126579 51EadieK, ParelF, Helvert-van PoppelMet al.Combining two" exact="antifungal" post="agents does not enhance survival of Galleria mellonella larvae"/>
 <result pre="Agents Chemother. 2014;58(1):48â€&quot;54.24126579 51EadieK, ParelF, Helvert-van PoppelMet al.Combining two antifungal" exact="agents" post="does not enhance survival of Galleria mellonella larvae infected"/>
 <result pre="the effects of photodynamic therapy alone and combined with standard" exact="antifungal" post="therapy on planktonic cells and biofilms of Fusarium spp."/>
 <result pre="Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs for" exact="antifungal" post="agents, version 10.0, valid from 2020-02-04. Available from: https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/AFST/Clinical_breakpoints/AFST_BP_v10.0_200204.pdf."/>
</results>
